Study of KRAS new predictive marker in a clinical laboratory

Clinical and Translational Oncology

Volumn 14, Issue 12, 2012, Pages 937-942

  Bando, Inmaculada ^a   Cillero, Lourdes ^a   Sanz Ortega, Julián ^a   Llovet, Patricia ^a   Pescador, Paula ^a   Ferrer, Milagros ^a   De La Hoya, Miguel ^a   Sastre, Javier ^a   García, Eduardo Díaz Rubio ^a   Caldés, Trinidad ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

ARMS S (TheraScreen: KRAS Mutation Kit); KRAS; m CRC; RH (KRAS StripAssay, Vienna Lab)

Indexed keywords

ALLELE; ARTICLE; CLINICAL EVALUATION; CODON; COLORECTAL CANCER; CONTROLLED STUDY; EXON; GENE FREQUENCY; GENETIC MARKER; HUMAN; HUMAN TISSUE; HYBRIDIZATION; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS;

EID: 84878560045     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0886-z     Document Type: Article

References (23)

1. Barbacid M (1987) Ras genes. Annu Rev Biochem 56:779-827
2. Grady WM, Markowitz SD (2002) Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 3:01-128
3. Allegra CJ, Jessup JM, Somerfield MR, Halminton SR, Hammond EH, Hayes DF et al (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096
4. Gallegos Ruiz MI, Floor K, Rijmen F, Grünberg K, Rodriguez JA (2007) EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol 29:257-264
5. Oliner K, Juan T, Suggs S, Wolf M, Sarosi I, Freeman DJ et al (2010) A comparability study of 5 commercial KRAS tests. Diagn Pathol 5:23
6. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N et al (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17:2503-2516
7. Thelwell N, Millington S, Solinas A, Booth J, Brown T (2000) Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res 28:3752-3761
8. Angulo B, García-García E, Martínez R, Suárez-Gauthier A, Conde E, Saletti P, Hidalgo M et al (2010) A commercial real-time PCR kit provides greater sensitivity tan direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol diagn JMC 12:292-299
9. Ausch C, Buxhofer-Ausch V, Oberkanins C, Holzer B, Minai-Pour M, Jahn S et al (2009) Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn 11:508-513
10. Viera AJ, Garrett JM (2005) Understanding inter observer agreement: the kappa statistic. Fam Med 37:360-363
11. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2:5705-2712
12. Hirsch FR, Bunn PA Jr (2009) EGFR testing in lung cancer is ready for prime time. Lancet Oncol 0:432-433
13. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379
14. Liévre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995
15. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med 359:1757-1765
16. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515
17. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634
18. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C et al (2005) Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7:413-421
19. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R et al (2008) High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130:247-253
20. Clayton SJ, Scott FM, Walker J, Callghan K, Haque K, Liloglou T, Field JK, Fox JC et al (2000) K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem 46:1929-1938
21. Nollau P, Wagener C (1997) Methods for detection of point mutations: performance and quality assessment. IFCC Scientific Division, Committee on Molecular Biology Techniques. Clin Chem 43:1114-1128
22. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F (2009) Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nature reviews. Clin Oncol 6:519-527
23. Martínez F, Fernández-Martos C, Quintana MAJ, Castell A, Llombart A, Iñiguez F, Guillem V, Dasi F (2011) APC and KRAS mutations in distal colorrectal polyps are related to smoking habits in men: results of a cross-sectional study. Clin Transl Oncol 13:664-671